Short Interest in Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Declines By 38.3%

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 148,118 shares, a decline of 38.3% from the July 30th total of 240,225 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 159,888 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DSNKY shares. Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

Shares of OTCMKTS:DSNKY opened at $18.38 on Monday. The business has a fifty day moving average price of $17.04 and a 200-day moving average price of $17.36. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. The company has a market capitalization of $34.24 billion, a PE ratio of 21.37, a PEG ratio of 2.52 and a beta of -0.18. Daiichi Sankyo has a 1-year low of $14.98 and a 1-year high of $27.50.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities analysts expect that Daiichi Sankyo will post 0.97 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.